My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

43.41 -0.75 (-1.70%)
Official Closing Price Updated: 7:00 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,345,594
Open 44.18
Bid (Size) 43.45 (2)
Ask (Size) 43.59 (1)
Prev. Close 44.16
Today's Range 43.19 - 44.46
52wk Range 42.96 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 5.71%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026
Via Stocktwits
Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)
From Bristol Myers Squibb
Via Business Wire

Performance

YTD
-23.6%
-23.6%
1 Month
-7.9%
-7.9%
3 Month
-7.0%
-7.0%
6 Month
-26.7%
-26.7%
1 Year
-14.8%
-14.8%

More News

Read More
The Smartest Dividend Stock to Buy With $1,000 Right Now
Via The Motley Fool
Topics Intellectual Property
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Via The Motley Fool
Topics Intellectual Property
Bristol Myers Announces Positive Outcomes From Multiple Myeloma Late-Stage Study
Via Stocktwits
J&J’s Investigational Plaque Psoriasis Drug Outperforms Bristol Myers’ Sotyktu In Study
Via Stocktwits
Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients
Via Benzinga
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
1 Reason to Buy Bristol Myers Squibb Stock
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Via MarketMinute
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Via MarketMinute
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
From Bristol Myers Squibb
Via Business Wire
Why Replimune Stock Plummeted by Almost 40% Today
Via The Motley Fool
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
Via FinancialNewsMedia
Topics Artificial Intelligence
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials
Via Benzinga
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
From Bristol Myers Squibb
Via Business Wire
3 Great High-Yield Dividend Stocks to Buy in September
Via The Motley Fool
BRISTOL-MYERS SQUIBB CO (NYSE:BMY): A High-Yield Dividend Stock with Strong Profitability
Via Chartmill
The Specter of Stagflation: A Looming Threat to Global Markets
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Via Benzinga
Topics ETFs Government
The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now
Via The Motley Fool
Topics Intellectual Property

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 43.41
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 09/25/25 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 96.46B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 96B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.